caa a22 4500 445334878 CHVBK 20180317142751.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1245/s10434-010-1336-1 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1336-1 An Elevated Body Mass Index Does Not Reduce Survival After Esophagectomy for Cancer [Elektronische Daten] [Marcovalerio Melis, Jill Weber, James McLoughlin, Erin Siegel, Sarah Hoffe, Ravi Shridhar, Kiran Turaga, George Dittrick, E. Dean, Richard Karl, Kenneth Meredith] Background: Incidences of esophageal cancer and obesity are both rising in the United States. The aim of this study was to determine the influence of elevated body mass index on outcomes after esophagectomy for cancer. Methods: Overall and disease-free survivals in obese (BMI≥30), overweight (BMI 25-29), and normal-weight (BMI 20-24) patients undergoing esophagectomy constituted the study end points. Survivals were calculated by the Kaplan-Meier method, and differences were analyzed by log rank method. Results: The study included 166 obese, 176 overweight, and 148 normal-weight patients. These three groups were similar in terms of demographics and comorbidities, with the exception of younger age (62.5 vs. 66.2 vs. 65.3years, P=0.002), and higher incidence of diabetes (23.5 vs. 11.4 vs. 10.1%, P=0.001) and hiatal hernia (28.3 vs. 14.8 vs. 20.3%, P=0.01) in obese patients. Rates of adenocarcinoma histology were higher in obese patients (90.8 vs. 90.9 vs. 82.5%, P=0.03). Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant treatment (47.6 vs. 54.5 vs. 66.2%, P=0.004). Response to neoadjuvant treatment, type of surgery performed, extent of lymphadenectomy, rate of R0 resections, perioperative complications, and administration of adjuvant chemotherapy were not influenced by BMI. At a median follow-up of 25months, 5-year overall and disease-free survivals were longer in obese patients (respectively, 48, 41, 34%, P=0.01 and 48, 44, 34%, P=0.01). Conclusions: In our experience, an elevated BMI did not reduce overall and disease-free survivals after esophagectomy for cancer. Society of Surgical Oncology, 2010 Melis Marcovalerio Division of Surgical Oncology, New York University School of Medicine, New York, New York, USA aut Weber Jill Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut McLoughlin James Department of Surgery, Medical College of Georgia, Augusta, Georgia aut Siegel Erin Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL, USA aut Hoffe Sarah Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Shridhar Ravi Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Turaga Kiran Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Dittrick George Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Dean E. Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Karl Richard Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Meredith Kenneth Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 824-831 1068-9265 18:3<824 2011 18 10434 https://doi.org/10.1245/s10434-010-1336-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1336-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Melis Marcovalerio Division of Surgical Oncology, New York University School of Medicine, New York, New York, USA aut NATIONALLICENCE 700 1- Weber Jill Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- McLoughlin James Department of Surgery, Medical College of Georgia, Augusta, Georgia aut NATIONALLICENCE 700 1- Siegel Erin Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Hoffe Sarah Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Shridhar Ravi Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Turaga Kiran Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Dittrick George Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Dean E. Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Karl Richard Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Meredith Kenneth Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 824-831 1068-9265 18:3<824 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer